| Code | CSB-RA011046MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Anifrolumab-FNIA, designed to target interferon alpha and beta receptor subunit 1 (IFNAR1). IFNAR1 is a critical component of the type I interferon receptor complex, which mediates cellular responses to interferon-alpha and interferon-beta signaling. Upon ligand binding, IFNAR1 heterodimerizes with IFNAR2, initiating JAK-STAT signaling cascades that regulate immune responses, antiviral defense, and inflammatory processes. Dysregulated type I interferon signaling is implicated in various autoimmune conditions, particularly systemic lupus erythematosus (SLE), where persistent interferon activation contributes to disease pathogenesis and tissue damage.
Anifrolumab-FNIA is a human IgG1 kappa monoclonal antibody that blocks type I interferon signaling by binding to IFNAR1, preventing receptor-mediated downstream signaling. This biosimilar antibody serves as a valuable research tool for investigating type I interferon biology, studying IFNAR1-mediated signaling pathways, and exploring therapeutic mechanisms in autoimmune disease models. It enables researchers to examine the role of interferon signaling in inflammation, immune regulation, and disease progression.
There are currently no reviews for this product.